MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
A Single-arm Phase Ia/Ib Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Patients With Advanced Melanoma Harboring NRAS Aberration(Ia)and NRAS/NF1 Mutation(Ib)
Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Suspended
Sponsor R\&D strategy adjustment
This PHASE1 trial investigates Melanoma and is currently suspended. Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Suspended PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Suspended PHASE1
Status: Unknown Status → Suspended
-
Apr 2023 — Apr 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
May 2022 — Apr 2023 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Jan 2021 — May 2022 [monthly]
Recruiting PHASE1
-
May 2019 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .